What is Solid Biosciences Inc.'s market cap?

Solid Biosciences Inc. (SLDB) has a market capitalization of $776.8M and trades on NASDAQ.

Who are Solid Biosciences Inc.'s competitors?

Solid Biosciences Inc.'s key competitors include Avidity Biosciences, Lexeo Therapeutics, Biogen Inc., and others. These companies compete in similar markets and product categories.

Who does Solid Biosciences Inc. partner with?

Solid Biosciences Inc.'s notable partners include Ultragenyx Pharmaceutical Inc., Mayo Foundation for Medical Education and Research, University of Washington, and others.

What subsidiaries does Solid Biosciences Inc. have?

Solid Biosciences Inc.'s subsidiaries include AavantiBio Inc..

Where is Solid Biosciences Inc. headquartered?

Solid Biosciences Inc. is headquartered in United States of America and employs approximately 88 people. It has been publicly traded since 2018.

Solid Biosciences Inc.

SLDB

Solid Biosciences is a life sciences company dedicated to developing gene therapies for rare neuromuscular and cardiac diseases.

Market cap

$776.77M+41.7%

Net income-$191.8M-37.3%

Free cash flow-$172.9M-61.1%

EPS (diluted)-$1.95+35.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

EPS-$0.52Miss by $0.12

Read the full report

Next report

Aug 11, 2026 (In 1 week)

EPS estimate-$0.43

Financials

Q1 2026

Income statement

See full

Operating income-$57.3M-43.1%

Net income-$56.7M-44.4%

EPS (diluted)-$0.52+11.9%

Balance sheet

See full

Cash & equivalents$297.1M+41.1%

Total debt$20.7M-12.5%

Total equity$374.1M+27.1%

Total assets$422.9M+23.0%

Cash flow

See full

Operating cash flow-$47.2M-48.3%

CapEx$165.0K+31.0%

Free cash flow-$47.4M-48.2%

Valuation & ratios

Valuation

See full

Market cap$776.77M+41.7%

Enterprise value$500.33M+16.8%

Returns & leverage

See full

Return on equity-57.4%+2.2pp

Debt / equity0.1×0.0×

Current ratio13.1×+2.2×

Competitors

By market cap

Biogen$29.5B+56.0%

Insmed$22.7B+17.5%

Dyne Therapeutics, Inc.$4.2B+222%

Sarepta Therapeutics, Inc.$1.7B+23.2%

Solid Biosciences Inc.$776.8M+42.7%

Regenxbio$621.6M+40.4%

Lexeo Therapeutics, Inc.$351.0M+52.6%

Atrium Therapeutics $197.9M-95.2%

By revenue growth

Insmed+115%

Sarepta Therapeutics, Inc.+9.9%

Biogen+0.3%

Regenxbio-44.0%

By net margin

Biogen8.81%-6.5pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Insmed-144.44%+121pp

Regenxbio-330.23%-230pp

Solid Biosciences Inc.-1,062.28%—

Profile

Solid Biosciences is a life sciences company dedicated to developing gene therapies for rare neuromuscular and cardiac diseases. The company leverages a proprietary innovation platform to design genetic medicines, including novel viral capsids and expression cassettes, aimed at treating underserved patient populations. Its core value proposition centers on advancing transformative treatments that address the underlying genetic causes of fatal conditions like Duchenne muscular dystrophy.

Competitive position

Solid Biosciences is a clinical-stage developer of specialized AAV gene therapies with a proprietary capsid platform designed for enhanced muscle and cardiac targeting.

GeographiesUnited States, Canada, European Union, United Kingdom

Customer segmentsPatients, Healthcare providers, Biotechnology partners

Business modelR&D intensive, IP licensing, Biopharmaceutical development

SuppliersContract Development and Manufacturing Organizations (CDMOs), Academic research institutions, Viral vector suppliers

CustomersSpecialty pharmacies, Hospitals, Clinical trial sites, Biotechnology licensees

CountryUnited States of America

Listed2018

Employees88.0

CEOAlexander G. Cumbo

SectorHealthcare

IndustryBiotechnology

Websitesolidbio.com

FilingsSEC EDGAR

Questions, answered.

What is Solid Biosciences Inc.'s market cap?: Solid Biosciences Inc. (SLDB) has a market capitalization of $776.8M and trades on NASDAQ.
Who are Solid Biosciences Inc.'s competitors?: Solid Biosciences Inc.'s key competitors include Avidity Biosciences, Lexeo Therapeutics, Biogen Inc., and others. These companies compete in similar markets and product categories.
Who does Solid Biosciences Inc. partner with?: Solid Biosciences Inc.'s notable partners include Ultragenyx Pharmaceutical Inc., Mayo Foundation for Medical Education and Research, University of Washington, and others.
What subsidiaries does Solid Biosciences Inc. have?: Solid Biosciences Inc.'s subsidiaries include AavantiBio Inc..
Where is Solid Biosciences Inc. headquartered?: Solid Biosciences Inc. is headquartered in United States of America and employs approximately 88 people. It has been publicly traded since 2018.